ONCOS-102

November 11, 2016November 11, 2016

Targovax Granted European Patent for Vaccine to Treat Mesothelioma, Now in Clinical Trial

News

Targovax has been granted a European patent for its lead product ONCOS-102, a cancer vaccine that is being clinically evaluated in mesothelioma, with tests planned for other solid tumors. The composition of matter patent, ... Read more

November 2, 2016November 2, 2016

Targovax Reports Promising Early Data on Vaccine Now in Mesothelioma Clinical Trial

News

Targovax recently presented preclinical and clinical results of the anti-tumor efficacy of its cancer vaccine ONCOS-102 for the treatment of malignant mesothelioma. The presentation, “OR52: Anti-tumor potency of cancer vaccine ... Read more

July 26, 2016July 26, 2016

Positive Preclinical Results Reported in Mesothelioma Model for ONCOS-102

News

Results from a preclinical study using a mesothelioma animal model demonstrate a synergic effect of ONCOS-102, a genetically modified adenovirus, in combination with pemetrexed and cisplatin. “These findings give a strong ... Read more

July 21, 2016July 21, 2016

First Patient Recruited in Malignant Pleural Mesothelioma PhaseIb/II Trial

News

Scandinavian-based Targovax recently recruited the first patient for the Phase Ib/II study examining ONCOS-102 in combination with pemetrexed and cisplatin for the treatment of malignant pleural mesothelioma (MPM), a rare, aggressive cancer ... Read more